Richard Weiten, MD, and colleagues designed a study to determine the potential utility of antibody-drug conjugates (ADCs) targeting TROP-2 in both localized penile squamous cell carcinoma (PSCC) and patient-matched distant metastases. Their results were presented at the 2024 American Urological Association Annual Meeting. ...
Testicular, Penile, and Rare Malignancies
Advertisement
Latest News
Dr. Spiess highlights prevalence of TERT expression and an increase in TROP-2 mRNA expression levels in PSCC patients.
The primary end point was establishing the risk of relapse connected with both surgical approaches.
Dr. Mollica continues her discussion on prognostic factors and clinical outcomes in PSCC.
Dr. Mollica highlights her recent research investigating prognostic factors and clinical outcomes for patients with PSCC.
The IGCCCG was used to compare the survival probabilities of patients with testicular GCTs with or without teratoma.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Advertisement
Advertisement
Latest News
Data on the type of treatment received in each line of therapy, as well as the attrition rates, were recorded.
In patients with RCC, around 20% demonstrate non-clear cell histology, including various histology types.
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
